Acne inversa Eine Dapson-sensitive Dermatose

Hofer, Thomas Franz; Itin, Peter

doi:10.1007/s001050170015

Cited by 38 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[68][69][70] Dapsone Dapsone has been found to be helpful in a small number of HS patients and is a reasonable therapeutic alternative for recalcitrant disease. 71 In a series of 5 patients, clinical improvement was noted in all 5 within 4 to 12 weeks, using doses between 25 and 150-mg daily. 72 All patients required maintenance therapy with dapsone at doses between 50 and 150 mg/d to sustain their disease control.…”

Section: Oral Retinoidsmentioning

confidence: 97%

Painful Hidradenitis Suppurativa

Smith

Chao

Teitelbaum

2010

The Clinical Journal of Pain

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronically relapsing skin disorder characterized by recurring inflammatory lesion in hair and apocrine gland-bearing skin creases in the axilla; groin or perineum, buttocks, and/or breast. HS may lead to painful eruptions and malodorous discharge significantly detracting from quality of life. HS causes a high degree of morbidity with the highest scores obtained for the level of pain caused by the disease. The majority of patients rated their pain on a Numerical Rating Scale-11 ranging from 4/10 to 10/10 and described it at various times as hot, burning, pressure, stretching, cutting, sharp, taut, splitting, gnawing, pressing, sore, throbbing, and aching. Despite the severe pain associated with this disease, HS has been essentially ignored in the pain medicine literature. It is hoped that greater understanding of the diagnosis, pathophysiology, and potential treatment options available for patients with HS, may help put pain specialists in a better position to contribute to the overall care of patients with significantly painful HS. This article reviews HS and pain. Potential mechanisms of modulating nociceptive processes in the skin are presented. A greater understanding of the diagnosis, pathophysiology, and potential treatment options for HS patients may help providers to be better able to contribute to care of patients with painful hidradenitis suppurativa.

show abstract

Section: Oral Retinoidsmentioning

confidence: 97%

Painful Hidradenitis Suppurativa

Smith

Chao

Teitelbaum

2010

The Clinical Journal of Pain

View full text Add to dashboard Cite

show abstract

“…Several studies involving oral dapsone have been published with mixed results 102–104. The most important study was conducted in 2011.…”

Section: Treatmentmentioning

confidence: 99%

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

Napolitano¹,

Megna²,

Тимощук³

et al. 2017

CCID

186

164

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring. HS is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture, and immune responses (perifollicular lympho-histiocytic inflammation), finally leading to the development of clinical HS lesions. HS has a destructive impact on the patient’s quality of life, being a very challenging disease. Available treatments are limited, mostly off-label and with high variability in the reported efficacy. Fortunately, a monoclonal antibody against tumor necrosis factor alpha has been recently approved for treatment of moderate to severe HS, offering patients a promising new option. This review focuses on the main features of HS, including epidemiology, clinical aspects, pathogenesis, severity classifications, comorbidities, and currently available treatments.

show abstract

“…Dapsone combines several of these qualities, and 2 smaller case series have suggested it to be an effective drug in the treatment of HS. In 2001 Hofer and Itin [16] described the beneficial outcome of dapsone treatment in 5 women, and in 2006 Kaur and Lewis [17] published similar results from another 5 patients. In both reports, only positive outcomes were presented, and it was therefore decided to review a larger series of cases reporting all outcomes in order to provide firmer data for the evaluation of the potential of dapsone in this debilitating disease.…”

Section: Introductionmentioning

confidence: 60%

Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients

et al. 2011

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is an inflammatory skin disease with a chronic intermittent course. HS is difficult to treat, and the evidence for the effect of most treatments consists of smaller open studies. The use of dapsone in the treatment of HS is based on a few published cases successfully treated. Objective: To evaluate the potential of dapsone treatment for HS in an open case series. Methods: An exploratory and retrospective review of case notes from HS patients treated with dapsone was performed. Patients were included irrespective of treatment outcome. Prior to the treatment the level of glucose-6-phosphate dehydrogenase in the blood was tested for all patients. Results: A total of 24 HS patients were included and treated with dapsone. Improvement was seen in 9 out of 24 (38%) treated patients, whereas 15 out of 24 (62%) did not experience any improvement. None of the 4 cases with severe disease experienced improvement. Side effects leading to discontinuation of the treatment occurred in 2 of 24 patients (8%). Recurrence of disease at the cessation of treatment was described as rapid. Limitations: The study is limited by lacking a control group. Conclusion: Therapy with dapsone for patients with HS is possible, particularly in milder cases. The effect may be due to either antibacterial or anti-inflammatory effects of the drug, or both. Rapid recurrence after stopping treatment however suggests that anti-inflammatory effects may predominate. The effect appears to be smaller than that reported with combination therapy using clindamycin and rifampicin. To clarify the true effect of dapsone future randomized controlled trials are necessary.

show abstract

Acne inversa Eine Dapson-sensitive Dermatose

Cited by 38 publications

References 19 publications

Painful Hidradenitis Suppurativa

Painful Hidradenitis Suppurativa

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients

Contact Info

Product

Resources

About